Loading market dashboard
Biodesix, Inc.
BDSXHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
The mean of analysts' price targets for Biodesix (BDSX) points to a 104.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will participate in three upcoming investor conferences:
Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals
The mean of analysts' price targets for Biodesix (BDSX) points to a 103.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to a loss of $1.6 per share a year ago.
Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo.
LOUISVILLE, Colo., April 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2026 after the close of trading on Monday, May 4. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Biodesix (NASDAQ: BDSX - Get Free Report) and Bausch + Lomb (NYSE: BLCO - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation. Insider and Institutional Ownership 21.0% of Biodesix shares
Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture
Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing
A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test's consistent clinical performance across nodule sizes and patient populations A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test's consistent clinical performance across nodule sizes and patient populations
The mean of analysts' price targets for Biodesix (BDSX) points to an 86.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here is how Biodesix, Inc. (BDSX) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month price objective among
